Percutaneous coronary intervention with drug-eluting stent for unprotected left main trunk disease: Safety and efficacy compared with bare metal stent-which coronary stent should be used for left main trunk disease? BMS or DES? (DES-side)

Circulation Journal

Volumn 75, Issue 5, 2011, Pages 1250-1254

  Kadota, Kazushige ^a   Mitsudo, Kazuaki ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Bare metal stents; Drug eluting stent; Restenosis; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL;

ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; SAFETY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNPROTECTED MAIN TRUNK CORONARY ARTERY DISEASE;

CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; METALS; STENTS; TREATMENT OUTCOME;

EID: 79955683920     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0307     Document Type: Article

References (38)

1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570.
2. Cohen MV, Gorlin R. Main left coronary artery disease: Clinical experience from 1964-1974. Circulation 1975; 52: 275-285.
3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong ATL, Kinnaird T, et al. Late stent thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1466-1467.
4. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
5. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50: 491-497.
6. Pandya SB, Kim YH, Meyers SN, Davidson CJ, Flaherty JD, Park DW. Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis. JACC Cardiovasc Interv 2010; 3: 602-611.
7. Han Y, Wang S, Jing Q, Li Y, Liu H, Ma Y, et al. Comparison of long-term efficacy of the paclitaxel-eluting stent versus the baremetal stent for treatment of unprotected left main coronary artery disease. Am J Cardiol 2009; 103: 194-198.
8. Palmerini T, Barlocco F, Santarelli A, Bacchi-Reggiani L, Savini C, Baldini E, et al. A comparison between coronary artery bypass grafting surgery and drug eluting stent for the treatment of for the treatment of unprotected left main (aged > or 75 years). Eur Heart J 2007; 28: 2714-2719.
9. Schrale RG, van Gaal W, Channon KM, Forfar JC, Ormerod OJ, Banning AP. Long-term outcomes of percutaneous coronary intervention for unprotected left main coronary artery disease. Int J Cardiol 2008; 130: 185-189.
10. Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 2009; 120: 400-407.
11. Tamburino C, Di Salvo ME, Capodanno D, Palmerini T, Sheiban I, Margheri M, et al. Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes. Am J Cardiol 2009; 103: 187-193.
12. Tamburino C, Di Salvo ME, Capodanno D, Marzocchi A, Sheiban I, Margheri M, et al. Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry. Eur Heart J 2009; 30: 1171-1179.
13. Gao RL, Xu B, Chen JL, Yang YJ, Qiao SB, Li JJ, et al. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: Comparison with bare-metal stent implantation. Am Heart J 2008; 155: 553-561.
14. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drugeluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-2319.
15. Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, Rabbat MG, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 2009; 122: 581.e1-e10.
16. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
17. de la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51: 986-990.
18. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
19. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009; 53: 1760-1768.
20. Vaquerizo B, Lefèvre T, Darremont O, Silvestri M, Louvard Y, Leymarie JL, et al. Unprotected left main stenting in the real world: Two-year outcomes of the French left main taxus registry. Circulation 2009; 119: 2349-2356.
21. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005; 111: 791-795.
22. Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Ueda H, Kawai K, et al. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: Insights from the j-Cypher registry. Circulation 2009; 120: 1866-1874.
23. Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, et al. Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: The DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol 2008; 51: 2212-2219.
24. Chieffo A, Magni V, Latib A, Maisano F, Ielasi A, Montorfano M, et al. 5-Year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions: The Milan experience. JACC Cardiovasc Interv 2010; 3: 595-601.
25. Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol 2010; 56: 117-124.
26. Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 2009; 120: 400-407.
27. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Captu R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
28. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drugeluting stents. N Engl J Med 2010; 362: 1374-1382.
29. Cosgrave J, Corbett SJ, Melzi G, Babic R, Biondi-Zoccai GG, Airoldi F, et al. Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol 2007; 100: 41-44.
30. Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 2009; 54: 1924-1931.
31. Shiode N, Shirota K, Tsunoda F, Kato Y, Fujiwara M, Mimura A. Late progression after sirolimus-eluting stent implantation for de novo lesions. Circ J 2010; 74: 1104-1110.
32. Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al: Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol 2010; 106: 329-336.
33. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Leon MB. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol 2009; 103: 923-929.
34. Surmely JF, Kinoshita Y, Dash D, Matsubara T, Terashima M, Ehara M, et al. Stent strut fracture-induced restenosis in a bifurcation lesion treated with the crush stenting technique. Circ J 2006; 70: 936-938.
35. Ino Y, Toyoda Y, Tanaka A, Ishii S, Kusuyama Y, Kubo T, et al. Predictors and prognosis of stent fracture after sirolimus-eluting stent implantation. Circ J 2009; 73: 2036-2041.
36. Chakravatory T, White AJ, Buch M, Naik H, Docotor N, Schapira J, et al. Meta-analysis of incidence, clinical characteristics and implication of stent fracture. Am J Cardiol 2010; 106: 1075-1080.
37. Kim U, Seol SH, Kim DI, Kim DK, Jang JS, Yang TH, et al. Clinical outcomes and the risk factors of coronary artery aneurysms that developed after drug-eluting stent implantation. Circ J 2011; 75: 861-867.
38. Kaneko H, Kijima M. Role of bare-metal stents for left main coronary artery disease in the era of drug-eluting stents: Which coronary stent should be used for left main trunk disease? BMS or DES? (BMS-Side) Circ J 2011; 75: 1243-1249.